ANI Pharmaceuticals, Inc. (ANIP) Stock Analysis

Company Overview

The market values ANI Pharmaceuticals, Inc. (ANIP) at $1.64B. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 970.

The 52-week range on file runs from $70.15 to $99.50. ANIP last closed at $71.23 on September 4, 2026. That is −$0.76 (−1.06%) against the previous close. The latest close sits 1.54% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $883.37M. Against the prior fiscal year total of $614.38M, that is a change of +43.78%. Net income for the same year was $78.34M. The reported profit margin is 11.07%. That is 14.2 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to 4.54.

Across the 4 fiscal years on file, revenue moves from $316.39M in 2022 to $883.37M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 15.69. That is 18.56% below the Drug Manufacturers - Specialty & Generic median of 19.27. On forward earnings the ratio is 6.82. Measured against sales, the shares trade at 1.67 times revenue. On price-to-sales that is 27.17% below the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.45. Daily returns over the trailing 10 years annualize to a volatility of 48.06%. Over the trailing twelve months the price has returned −25.80%. Across 10 years the annualized return works out at +1.75%.

Growth & Income

No dividend is on file for ANIP.

So far in 2026 the price is −9.77%. Across the complete calendar years on file, 2021 returned +58.68% and 2020 returned −52.91%. Of the 9 complete calendar years on file, 6 finished higher.